Repository logo
 

No evidence for selection of HIV-1 with enhanced gag-protease or nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.

dc.contributor.authorChopera, Denis Rutendo.
dc.contributor.authorMann, Jaclyn Kelly.
dc.contributor.authorMwimanzi, Philip.
dc.contributor.authorOmarjee, Saleha.
dc.contributor.authorKuang, Xiaomei T.
dc.contributor.authorNdabambi, Nonkululeko.
dc.contributor.authorGoodier, Sarah A.
dc.contributor.authorMartin, Eric.
dc.contributor.authorNaranbhai, Vivek.
dc.contributor.authorAbdool Karim, Salim Safurdeen.
dc.contributor.authorAbdool Karim, Quarraisha.
dc.contributor.authorBrumme, Zabrina L.
dc.contributor.authorNdung'u, Peter Thumbi.
dc.contributor.authorWilliamson, Carolyn.
dc.contributor.authorBrockman, Mark A.
dc.date.accessioned2016-10-24T07:19:07Z
dc.date.available2016-10-24T07:19:07Z
dc.date.created2013
dc.date.issued2013
dc.descriptionCAPRISA, 2013.en_US
dc.description.abstractBackground: Use of antiretroviral-based microbicides for HIV-1 prophylaxis could introduce a transmission barrier that inadvertently facilitates the selection of fitter viral variants among incident infections. To investigate this, we assessed the in vitro function of gag-protease and nef sequences from participants who acquired HIV-1 during the CAPRISA 004 1% tenofovir microbicide gel trial. Methods and Results: We isolated the earliest available gag-protease and nef gene sequences from 83 individuals and examined their in vitro function using recombinant viral replication capacity assays and surface protein down regulation assays, respectively. No major phylogenetic clustering and no significant differences in gag-protease or nef function were observed in participants who received tenofovir gel versus placebo gel prophylaxis. Conclusion: Results indicate that the partial protective effects of 1% tenofovir gel use in the CAPRISA 004 trial were not offset by selection of transmitted/early HIV-1 variants with enhanced Gag-Protease or Nef fitness.en_US
dc.identifier.citationChopera, D.R., Mann, J.K., Mwimanzi, P., Omarjee, S., Kuang, X.T., Ndabambi, N., Goodier, S., Martin, E., Naranbhai, V., Karim, S.A. and Karim, Q.A. 2013. No evidence for selection of HIV-1 with enhanced Gag-Protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. PloS one 8(8), e71758.en_US
dc.identifier.urihttp://dx.doi.org/10.1371/journal.pone.0071758.en_US
dc.identifier.urihttp://hdl.handle.net/10413/13535
dc.language.isoenen_US
dc.titleNo evidence for selection of HIV-1 with enhanced gag-protease or nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.en_US
dc.typePeer reviewed journal articleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Chopera_Denis_R_2013.pdf
Size:
1.2 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.64 KB
Format:
Item-specific license agreed upon to submission
Description: